Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles

Kianfar, Ehsan

doi:10.1186/s12951-021-00896-3

Cited by 282 publications

(127 citation statements)

References 243 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several classes of nanocarriers (i.e., lipid-based nanoparticles, metallic nanoparticles, nanocrystals, polymeric nanoparticles and protein-based nanoparticles) or their hybrids have been employed to deliver hesperidin or hesperetin in preclinical BC models, with the aim of overcoming their poor bioavailability. Each of these nanocarrier classes is associated with a distinct set of advantages and limitations ( Table 2 ) ( Colone et al, 2020 , García-Pinel et al, 2019 , Gigliobianco et al, 2018 , Kianfar, 2021 , Mitchell et al, 2021 , Sharma et al, 2018 ), thus emphasising the importance of selecting the most appropriate nanocarrier system for a particular compound. In a study, Sulaiman et al (2020) loaded hesperidin onto GSH-coated gold nanoparticles (Hsp-AuNPs) via electrostatic attraction between the amine group of hesperidin and the carboxyl group of GSH, and assessed this nanoformulation in both in vitro and in vivo BC models.…”

Section: Strategies To Enhance Bioavailability Of Hesperidin and Hesperetinmentioning

confidence: 99%

Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects

Yap

Sekar

et al. 2021

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

Breast cancer (BC) has high incidence and mortality rates, making it a major global health issue. BC treatment has been challenging due to the presence of drug resistance and the limited availability of therapeutic options for triple-negative and metastatic BC, thereby urging the exploration of more effective anti-cancer agents. Hesperidin and its aglycone hesperetin, two flavonoids from citrus species, have been extensively evaluated for their anti-cancer potentials. In this review, available literatures on the chemotherapeutic and chemosensitising activities of hesperidin and hesperetin in preclinical BC models are reported. The safety and bioavailability of hesperidin and hesperetin as well as the strategies to enhance their bioavailability are also discussed. Overall, hesperidin and hesperetin can inhibit cell proliferation, migration and BC stem cells as well as induce apoptosis and cell cycle arrest in vitro . They can also inhibit tumour growth, metastasis and neoplastic changes in tissue architecture in vivo . Moreover, the co-administration of hesperidin or hesperetin with doxorubicin, letrozole or tamoxifen can enhance the efficacies of these clinically available agents. These chemotherapeutic and chemosensitising activities of hesperidin and hesperetin have been linked to several mechanisms, including the modulation of signalling pathways, glucose uptake, enzymes, miRNA expression, oxidative status, cell cycle regulatory proteins, tumour suppressor p53, plasma and liver lipid profiles as well as DNA repair mechanisms. However, poor water solubility, extensive phase II metabolism and apical efflux have posed limitations to the bioavailability of hesperidin and hesperetin. Various strategies for bioavailability enhancement have been studied, including the utilisation of nano-based drug delivery systems and the co-administration of hesperetin with other flavonoids. In particular, nanoformulated hesperidin and hesperetin possess greater chemotherapeutic and chemosensitising activities than free compounds. Despite promising preclinical results, further safety and efficacy evaluation of hesperidin and hesperetin as well as their nanoformulations in clinical trials is required to ascertain their potentials to be developed as clinically useful agents for BC treatment.

show abstract

Section: Strategies To Enhance Bioavailability Of Hesperidin and Hesperetinmentioning

confidence: 99%

Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects

Yap

Sekar

et al. 2021

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

show abstract

“…Simultaneously, serum phosphorus clearance of CRRT is linked to the prognosis of critically ill patients ( 7 , 8 ). ALB is one of the most critical proteins in the human plasma because it may maintain plasma colloid osmotic pressure, engage in material transport in blood circulation, and facilitate communication among the intracellular fluid, extracellular fluid, and tissue fluid ( 9 ). Hypoalbuminemia is widespread in patients with critical illnesses, and it is widely recognized as being linked to patient deterioration and higher death ( 10 , 11 ).…”

Section: Introductionmentioning

confidence: 99%

Serum Albumin Before CRRT Was Associated With the 28- and 90-Day Mortality of Critically Ill Patients With Acute Kidney Injury and Treated With Continuous Renal Replacement Therapy

Wang

Sun

et al. 2021

Front. Nutr.

View full text Add to dashboard Cite

Introduction: Although low serum albumin (ALB) may worsen acute kidney injury (AKI), additional study is needed to establish the connection between ALB and the prognosis of critically ill patients with AKI and treated with continuous renal replacement therapy (CRRT).Methods:A secondary analysis of a bi-center, retrospective, and observational study, such as critically ill patients with AKI and treated with CRRT from January 2009 to September 2016. The univariate analysis, multi-factor regression analysis, sensitivity analysis, and curve-fitting analysis were applied to explore the association of ALB with the 28 and 90 days mortality of critically ill patients with AKI and treated with CRRT, and the removal efficiency of serum phosphorus.Results: From January 2009 to September 2016, 1,132 cases with AKI and treated with CRRT met the inclusion criteria and enrolled in this study. We found that the higher ALB before CRRT, the lower the 28- and 90-day mortality of patients with AKI and treated with CRRT, the higher removal efficiency of serum phosphorus, the adjusted hazard ratio (HR) value for 28-day mortality in the four models were separately 0.92 (0.90, 0.95), 0.91 (0.89, 0.94), 0.92 (0.89, 0.95), and 0.92 (0.89, 0.95); the adjusted HR value for 90 day mortality in the four models were 0.91 (0.89, 0.94), 0.92 (0.89, 0.95), 0.92 (0.89, 0.95), and 0.92 (0.89, 0.96); the adjusted OR value for the removal efficiency of serum phosphorus in the four models were separately −0.04 (−0.07, −0.01), −0.05 (−0.08, −0.01), −0.04 (−0.08, −0.01), and −0.04 (−0.08, −0.01). The sensitivity analysis and curve-fitting analysis also showed that ALB before CRRT was correlated with the 28 and 90 days mortality of critically ill patients with AKI and treated with CRRT and the removal efficiency of serum phosphorus.Conclusion: The higher the serum ALB before CRRT, the lower the mortality of critically ill patients with AKI and treated with CRRT, and the higher the clearance efficiency of serum phosphorus.

show abstract

“…Over the past few decades, albumin has emerged as a powerful macromolecular carrier in medical therapeutic and diagnostic [27] applications [20]. Its role in binding to the neonatal Fc receptor (FcRn) was investigated by Anderson et al, and its pH-dependent manner of binding was also clarified [28,29].…”

Section: Role Of Albumin In Humans and Its Potentialmentioning

confidence: 99%

“…The albumin is a family of globular proteins, the most common of which are the serum albumins [19]. Abraxane ® is a drug formulation based on SANPs that garnered more than 600 million dollars in sales in 2012 alone [20] and saw 52% sales growth in 2013 [21]. Furthermore, Abraxane ® is considered by experts to be one of the main approaches to treating all types of cancer in the near future [22,23].…”

Section: Introductionmentioning

confidence: 99%

Serum Albumin Nanoparticles: Problems and Prospects

Hornok

2021

Polymers

View full text Add to dashboard Cite

The present paper aims to summarize the results regarding serum albumin-based nanoparticles (NPs) for drug delivery purposes. In particular, it focuses on the relationship between their preparation techniques and synthesis parameters, as well as their successful clinical application. In spite of the huge amount of consumed material and immaterial sources and promising possibilities, products made from different types of albumin NPs, with the exception of a few, still have not been invented. In the present paper, promising applications of serum albumin nanoparticles (SANPs) for different biomedical purposes, such as carriers, delivery systems and contrast agents, are also discussed. The most frequent utilization of the NPs for certain diseases, i.e., cancer therapy, and future prospects are also detailed in this study.

show abstract

Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles

Cited by 282 publications

References 243 publications

Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects

Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects

Serum Albumin Before CRRT Was Associated With the 28- and 90-Day Mortality of Critically Ill Patients With Acute Kidney Injury and Treated With Continuous Renal Replacement Therapy

Serum Albumin Nanoparticles: Problems and Prospects

Contact Info

Product

Resources

About